TY - JOUR
T1 - β2-agonist clenbuterol induced changes in the distribution of white blood cells in rats
AU - Shirato, Ken
AU - Tanihata, Jun
AU - Motohashi, Norio
AU - Tachiyashiki, Kaoru
AU - Tomoda, Akio
AU - Imaizumi, Kazuhiko
PY - 2007
Y1 - 2007
N2 - Clenbuterol [CLE: 4-amino-α(t-butyl-amino)methyl-3,5-dichlorobenzyl alcohol] is well known as a potent β2-adrenergic agonist and non-steroidal anabolic drug, and thus it is generally used for sports doping and asthma therapy. Although the functions of immune cells such as white blood cells (WBCs) have shown to be modulated through β2- adrenoceptors, the effects of CLE on immune-responsive systems have not been elucidated systematically. Therefore, the effects of CLE on the number of WBCs were studied in rats. Male adult rats were divided into CLE-administered group and the control group to compare the number of total WBCs, neutrophils, monocytes, lymphocytes, eosinophils, and basophils. The administration (dose = 1.0 mg·kg-1 body weight·day-1, s.c.) of CLE was maintained for 30 days. CLE did not change the number of total WBCs during the experimental period. However, CLE increased significantly the number of neutrophils and monocytes, while CLE decreased drastically the number of lymphocytes and eosinophils. There was no significant change in the number of basophils between both groups. These results suggest that the administration of CLE induces drastic redistribution of WBCs in circulation without changing the number of total WBCs, and these responses of WBCs during the administration of CLE are sustained for at least 30 days.
AB - Clenbuterol [CLE: 4-amino-α(t-butyl-amino)methyl-3,5-dichlorobenzyl alcohol] is well known as a potent β2-adrenergic agonist and non-steroidal anabolic drug, and thus it is generally used for sports doping and asthma therapy. Although the functions of immune cells such as white blood cells (WBCs) have shown to be modulated through β2- adrenoceptors, the effects of CLE on immune-responsive systems have not been elucidated systematically. Therefore, the effects of CLE on the number of WBCs were studied in rats. Male adult rats were divided into CLE-administered group and the control group to compare the number of total WBCs, neutrophils, monocytes, lymphocytes, eosinophils, and basophils. The administration (dose = 1.0 mg·kg-1 body weight·day-1, s.c.) of CLE was maintained for 30 days. CLE did not change the number of total WBCs during the experimental period. However, CLE increased significantly the number of neutrophils and monocytes, while CLE decreased drastically the number of lymphocytes and eosinophils. There was no significant change in the number of basophils between both groups. These results suggest that the administration of CLE induces drastic redistribution of WBCs in circulation without changing the number of total WBCs, and these responses of WBCs during the administration of CLE are sustained for at least 30 days.
KW - β-agonist
KW - Clenbuterol
KW - Immune-responsive system
KW - Lymphocyte
KW - White blood cell
UR - http://www.scopus.com/inward/record.url?scp=34250804721&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34250804721&partnerID=8YFLogxK
U2 - 10.1254/jphs.FP0070267
DO - 10.1254/jphs.FP0070267
M3 - Article
C2 - 17558185
AN - SCOPUS:34250804721
SN - 1347-8613
VL - 104
SP - 146
EP - 152
JO - Journal of Pharmacological Sciences
JF - Journal of Pharmacological Sciences
IS - 2
ER -